Agomab Therapeutics became public via a Nasdaq IPO in February 2026, raising over $200 million to support its clinical-stage programs. The company specializes in organ-restricted ALK5 inhibitors aimed at fibrosis disorders with high unmet needs, including Fibrostenosing Crohn’s Disease and idiopathic pulmonary fibrosis. Agomab’s focused strategy emphasizes safety differentiation through localized drug targeting and robust intellectual property, but clinical development risks and complex market access remain key challenges. Upcoming pipeline milestones, particularly Phase 2 trials, will be critical near-term indicators for the company’s execution trajectory.